Silo Pharma, Inc. (SILO)
SILO moved a median of -0.76% 30 minutes after news, and -0.69% by the close. How SILO actually reacts to news — the realized, point-in-time move the market made, measured across 225 labeled events over the last three years with zero look-ahead.
SILO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 35% | 209 |
| 30-min | -0.76% | 33% | 215 |
| 60-min | -1.18% | 34% | 224 |
| to close | -0.69% | 45% | 222 |
| Middle 50% of SILO reactions | -3.98% to +0.82% |
|---|---|
| Median reaction (30-min) | -0.76% |
| Measured reactions | 225 |
Half of all Silo Pharma, Inc. news events land between -3.98% and +0.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SILO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SILO's baseline. Nothing else.
Recent SILO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Silo Pharma, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | +0.00% | |
| Form 8-K Silo Pharma, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | +10.37% | |
| Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility | Press release | GlobeNewswire | -1.25% | -5.63% | |
| Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio | Press release | GlobeNewswire | +0.00% | +10.18% | |
| Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum | Press release | GlobeNewswire | — | -8.12% | |
| Form 8-K Silo Pharma, Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -2.86% | -2.14% | |
| Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment | Press release | GlobeNewswire | -2.98% | +6.72% | |
| Form 8-K Silo Pharma, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.99% | |
| Form 10-Q Silo Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.62% | |
| Silo Pharma Granted European Patent Covering Novel PTSD Therapy | Press release | GlobeNewswire | -0.27% | — | |
| Form EFFECT Silo Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -18.63% | |
| Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform | Press release | GlobeNewswire | +2.60% | +1.30% | |
| Form S-8 Silo Pharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | +3.85% | |
| Form S-3 Silo Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | — | -3.08% | |
| Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program | Press release | GlobeNewswire | -1.02% | +0.64% | |
| Form D Silo Pharma, Inc. | SEC filing · Form D | SEC EDGAR | -1.78% | -3.66% | |
| Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform | Press release | GlobeNewswire | -3.86% | +10.09% | |
| Form 8-K Silo Pharma, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -3.93% | -5.71% | |
| Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -2.13% | -6.56% | |
| Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program | Press release | GlobeNewswire | -4.45% | -10.02% | |
| Form ARS Silo Pharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.18% | +5.08% | |
| Form DEF 14A Silo Pharma, Inc. For: Aug 14 | SEC filing · Form DEF | SEC EDGAR | +1.18% | +5.08% | |
| Form DEFA14A Silo Pharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.18% | +5.08% | |
| Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request | Press release | GlobeNewswire | +1.18% | +5.08% | |
| Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial | Press release | GlobeNewswire | +1.53% | +6.12% | |
| Form 8-K Silo Pharma, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -1.72% | |
| Form PRE 14A Silo Pharma, Inc. For: Aug 14 | SEC filing · Form PRE | SEC EDGAR | +0.65% | -1.72% | |
| Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | -2.24% | +5.34% | |
| Form 8-K Silo Pharma, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -8.65% | -2.08% | |
| Form 8-K Silo Pharma, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -2.42% | -18.88% | |
| Form 10-Q Silo Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.78% | +1.49% | |
| Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury | Press release | GlobeNewswire | -0.23% | -2.33% | |
| Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD | Press release | GlobeNewswire | -3.45% | -0.02% | |
| Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents | Press release | GlobeNewswire | -0.02% | -5.28% | |
| Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | Press release | GlobeNewswire | +3.11% | +29.59% | |
| Form EFFECT Silo Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.52% | +26.55% | |
| Form EFFECT Silo Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.21% | -4.31% | |
| Form POS AM Silo Pharma, Inc. | SEC filing · Form POS | SEC EDGAR | -0.42% | +1.94% | |
| Form POS AM Silo Pharma, Inc. | SEC filing · Form POS | SEC EDGAR | +1.52% | -0.74% | |
| Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy | Press release | GlobeNewswire | +3.50% | -10.76% | |
| Form 8-K Silo Pharma, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.58% | |
| Form 10-K Silo Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.84% | +2.88% | |
| Form 8-K Silo Pharma, Inc. For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | +1.81% | |
| Silo Pharma Announces Share Buyback Program | Press release | GlobeNewswire | -3.85% | +1.81% | |
| Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio | Press release | GlobeNewswire | -8.79% | -11.21% | |
| Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 | Press release | GlobeNewswire | -3.80% | +2.64% | |
| Form 8-K Silo Pharma, Inc. For: Dec 24 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -9.62% | |
| Form EFFECT Silo Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.87% | -0.83% | |
| Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD | Press release | GlobeNewswire | -4.94% | -13.07% | |
| Form S-1 Silo Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.63% | +0.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SILO section they belong to.
Where else SILO is measured.
SILO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Silo Pharma, Inc.'s median reaction calculated?
Every labeled SILO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 225 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of SILO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SILO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.